Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medi-CapsBOM:523144 +0.37%47 Return-on-Tangible-Equity is 14.58% as of Mar. 2026, which is 671% above its 10-year median of 1.89. GuruFocus rates BOM:523144 with a GF Score™ of 47/100 and a GF Value™ of ₹19.73 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,716 Real Estate companies, Medi-Caps ranks worse than 78.73% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Medi-Caps's annualized net income for the quarter that ended in Mar. 2026 was ₹121.7 Mil. Medi-Caps's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹834.7 Mil. Therefore, Medi-Caps's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 14.58%.
The historical rank and industry rank for Medi-Caps's Return-on-Tangible-Equity or its related term are showing as below:
BOM:523144'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -8.98 Med: 1.89 Max: 15.97
Current: -3.44
During the past 13 years, Medi-Caps's highest Return-on-Tangible-Equity was 15.97%. The lowest was -8.98%. And the median was 1.89%.
BOM:523144's Return-on-Tangible-Equity is ranked worse than 78.73% of 1716
companies
in the Real Estate industry
Industry Median: 4.27
vs BOM:523144: -3.44
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Medi-Caps Return-on-Tangible-Equity Related Terms
Medi-Caps Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Medi-Caps's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Real Estate - Diversified subindustry, Medi-Caps's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medi-Caps Return-on-Tangible-Equity vs Real Estate Industry
For the Real Estate industry and Real Estate sector, Medi-Caps's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Medi-Caps's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 14.58% mean?
Medi-Caps (BOM:523144) has a Return-on-Tangible-Equity of 14.58% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medi-Caps and its competitors. This is 671% above median its historical median of 1.89. According to the industry distribution chart, Medi-Caps ranks #1351 out of 1716 companies in the Real Estate industry, placing it in the top 78.7%.
Is Medi-Caps' Return-on-Tangible-Equity too high?
Medi-Caps' current Return-on-Tangible-Equity of 14.58% is 671% above median its 10-year median of 1.89. The Real Estate industry median Return-on-Tangible-Equity is 4.27. Medi-Caps' value of 14.58% is 241.5% above this industry median. Based on the distribution chart, Medi-Caps ranks #1351 out of 1716 companies in the Real Estate industry, which is in the bottom quartile relative to peers. Overall, Medi-Caps has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medi-Caps' Return-on-Tangible-Equity compare to competitors?
According to the Real Estate industry distribution chart, Medi-Caps ranks #1351 out of 1716 companies for Return-on-Tangible-Equity. This places Medi-Caps in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.27. Medi-Caps' value of 14.58% is 241.5% above this benchmark. While the company's 10-year median is 1.89 vs. the industry median of 4.27, Medi-Caps has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Real Estate company?
The median Return-on-Tangible-Equity among Real Estate companies is 4.27, based on 1,716 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medi-Caps's current Return-on-Tangible-Equity of 14.58% is 241.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medi-Caps and its competitors. For the Real Estate industry, the median Return-on-Tangible-Equity is 4.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medi-Caps's current Return-on-Tangible-Equity is 14.58%, which is 671% above median its own 10-year median of 1.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medi-Caps stock overvalued right now?
Based on GuruFocus' analysis, Medi-Caps (BOM:523144) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹19.73, compared to a current price of ₹26.92 — trading 36.4% above its estimated fair value. The current Return-on-Tangible-Equity is 14.58%, which is 671% above median its 10-year median of 1.89 and 241.5% above the Real Estate industry median of 4.27. Medi-Caps' overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Medi-Caps (BOM:523144), the current Return-on-Tangible-Equity is 14.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medi-Caps (BOM:523144) Overvalued in 2026?
Based on GuruFocus' analysis, Medi-Caps stock appears to be overvalued.
The current stock price of ₹26.92 is trading 36.4% above its estimated GF Value™ of ₹19.73.
GuruFocus considers Medi-Caps to be Significantly Overvalued.
Key valuation signals for BOM:523144:
Return-on-Tangible-Equity: 14.58% (671% above median its 10-year median of 1.89)
GF Value™: ₹19.73 vs. price of ₹26.92 (36.4% above fair value)
Industry Position: 241.5% above the Real Estate median (#1351 of 1716)
No single metric tells the full story. See the BOM:523144 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medi-Caps Ltd is an India-based company engaged in the real estate business witch city centric developments by way of Strategic Land acquisition and developing the residential and commercial properties. Its project include Medicaps Business Park. The group has two segments namely, the Pharma Division, and the Real Estate Division. The majority of its revenue is generated from the Pharma Division.
47GF Score
Get the complete analysis for BOM:523144
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:523144 has been successfully added to your 
